Go to ...

Nordens Ekonomi Norge

RSS Feed

23. februar 2019

Akcea Announces Its Access and Distribution Strategy for TEGSEDI™ (inotersen)

Euroinvestor.com A/S Euroinvestor.com A/S

BOSTON, Oct. 05, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), an affiliate of Ionis Pharmaceuticals, Inc.(NASDAQ: IONS), announced today that they are working together with Accredo® specialty pharmacy, a subsidiary of Express Scripts (NASDAQ: ESR..

More Stories From

Do NOT follow this link or you will be banned from the site!
Read previous post:
Akcea and Ionis Receive FDA Approval of TEGSEDI™ (inotersen) for the Treatment of the Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis in Adults

TEGSEDI provides powerful knockdown of TTR protein, delivering significant and sustained benefits in neuropathy and quality of life TEGSEDI is...